Expedite Identification of Early-Stage Dementia in a Mere 5 Minutes with Brainalyze
In the ongoing battle against dementia, a significant breakthrough has been made by Brainalyze, a company co-founded by Professor Sumeet Mahajan and Dr George Devitt. The University of Southampton will be licensing the intellectual property for this innovative venture.
Currently, dementia is the seventh leading cause of death worldwide, with approximately 57 million people diagnosed in 2021 and nearly 10 million new cases identified each year. The traditional diagnostic pathway for dementia is lengthy and resource-intensive, making early detection a critical need.
Brainalyze has developed a solution that addresses this issue: a minimally invasive, quick, and accessible finger-prick blood test designed to detect dementia at earlier stages compared to traditional diagnostic tools. This test, which takes only 5 minutes to administer, has reportedly achieved an accuracy of 93% in identifying and distinguishing Alzheimer's disease from other diseases that cause dementia.
The test, which has successfully completed the pre-clinical trial stage, is now progressing through various stages of clinical validation, collaborating with research institutions to refine and validate the technology. However, it is not yet widely available on the commercial market and may still be undergoing regulatory review or additional large-scale clinical trials to ensure its effectiveness and approval for clinical use.
Brainalyze's ultimate goal is to address the £100 billion worldwide spend on dementia treatment, care, and monitoring. To achieve this, they are launching their initial fundraising round to accelerate their path to market. They are seeking MedTech and BioTech specialist investors with experience in rapidly bringing healthtech to market and scaling it globally.
Professor Sumeet Mahajan, co-founder of Brainalyze, aims to build a billion-dollar business and pioneer national level dementia screening programs globally. With a scalable and cost-effective solution, Brainalyze's technology is aimed for deployment throughout the clinical pathway.
To stay updated on the latest developments, you can reach out to Brainalyze via their website or contact [email protected]. For the most up-to-date status, checking Brainalyze’s official announcements or recent scientific publications related to their biomarker research would provide the latest insights.
- In the realm of science and research, Brainalyze, a company co-founded by Professor Sumeet Mahajan and Dr George Devitt, has pioneered a technology that could revolutionize the diagnosis and treatment of chronic diseases such as Alzheimer's disease and other neurological disorders.
- This technology, currently undergoing clinical validation, is a finger-prick blood test designed to detect dementia at earlier stages than traditional diagnostic tools, achieving an accuracy of 93%.
- As dementia remains a significant global health issue, causing approximately 57 million diagnosed cases in 2021 and with nearly 10 million new cases identified each year, the need for a quicker and more accessible diagnostic solution is critical.
- To attain their goal of addressing the £100 billion worldwide spend on dementia treatment, care, and monitoring, Brainalyze is seeking MedTech and BioTech specialist investors with experience in rapidly bringing healthtech to market and scaling it globally.
- The company aims to build a billion-dollar business and pioneer national level dementia screening programs globally, making their technology cost-effective and scalable throughout the clinical pathway.
- With financial backing, Brainalyze's technology has the potential to impact not only the medical-conditions and mental-health sectors but also the finance scene, as it targets a substantial portion of the global healthcare spending on dementia.
